Probiotics Depression Meta-analysis: What the Evidence Says

Quick Answer

Probiotics Depression Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Individuals with depression exhibit distinct gut microbiota profiles, including reduced abundance of short-chain fatty acid (SCFA)-producing bacteria (e.g., Faecalibacterium and Roseburia) and elevated pro-inflammatory cytokines (e.g., IL-6, TNF-α), correlating with depression severity. [Haiyan Liu (2026); evidence level 1]
• This analysis addresses key limitations in existing evidence by focusing specifically on studies of probiotic monotherapy in unmedicated individuals, a design that minimizes confounding by psychotropic drugs. [Haiyan Liu (2026); evidence level 1]
• The emerging evidence supports that there is a bidirectional relationship between gut microbiota and depression, representing a paradigm shift in psychiatric research. [Mosavat Seyed Hamdollah (2026); evidence level 2]
• Animal studies have presented some compelling evidence to suggest a causal role of dysbiosis in depression-like behaviours. [Mosavat Seyed Hamdollah (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For probiotics depression meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Haiyan Liu (2026). Efficacy of probiotic intervention in unmedicated depression: a systematic review and meta-analysis. DOI: 10.3389/fpsyt.2025.1608238. PMCID: PMC12819584. PMID: 41573044. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12819584/
• Mosavat Seyed Hamdollah (2026). Effect of probiotic supplement on improvement of depressive symptoms in patients with substance-induced depressive disorder: a randomized, double-blind, placebo-controlled clinical trial. DOI: 10.1186/s12888-026-07903-7. PMCID: PMC13097662. PMID: 41826906. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13097662/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.